[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) filed a Form 4 disclosing routine equity awards to director Elizabeth M. Anderson on 26 June 2025.

• Restricted Stock Units (RSUs): Anderson received 3,142 shares of common stock at no cost, raising her direct beneficial ownership to 23,215 shares (inclusive of the new RSUs).
• Stock Option Grant: She was granted an option on 11,574 shares with a $37.48 exercise price, expiring 26 June 2035. The option vests in full on the earlier of the first anniversary of the grant or immediately prior to the next annual meeting, provided she remains a service provider.
• Indirect Holdings: Anderson also reports 26,990 shares held through the David W. Anderson 1996 Irrevocable Trust.
• No Dispositions: The filing records no sales of RVMD shares.

The transactions represent standard director compensation and have an immaterial impact on the company’s overall share count or governance structure. No performance metrics, strategic developments, or other material events were disclosed in this filing.

Insights

Financial Analyst

TL;DR: Routine director equity awards; negligible dilution; neutral for valuation.

This Form 4 shows a typical annual equity package: 3,142 RSUs plus an 11,574-share option at $37.48. No shares were sold, so there is no bearish signal. The aggregate 14.7 k shares represent less than 0.02 % of RVMD’s ~86 m basic shares, implying de minimis dilution. Because awards vest within a year, the option aligns director incentives with shareholder value but does not materially alter ownership structure.

Corporate Governance Specialist

TL;DR: Standard compensation; reinforces director alignment; governance status unchanged.

The grant follows normal independent-director compensation practices under RVMD’s 2020 Plan. A single-cliff vest aligns tenure with shareholder interests. Indirect trust holdings remain static, suggesting no hidden accumulation or disposal. The filing is compliant with Section 16(a) timing requirements and does not indicate any governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borellini Flavia

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		3,142	A	$0	25,024(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.48	06/26/2025		A		11,574		(2)	06/26/2035	Common Stock	11,574	$0	11,574	D

Explanation of Responses:

1. Includes 3,142 Restricted Stock Units.

2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Flavia Borellini	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RVMD RSUs were granted to Director Elizabeth M. Anderson?

3,142 restricted stock units were awarded on 26 June 2025.

What is the size and price of the new RVMD stock option grant?

An option covering 11,574 shares was granted with a $37.48 exercise price.

Did the filing report any sale of Revolution Medicines shares?

No. The Form 4 shows only acquisitions; no dispositions were reported.

What is Elizabeth M. Anderson’s total direct RVMD share ownership after the transactions?

She holds 23,215 shares directly, which include the newly granted RSUs.

When will the newly granted RVMD options fully vest?

They vest on the earlier of 26 June 2026 or immediately before the next annual meeting, contingent on continued service.